Pembrolizumab and lenvatinib for anaplastic thyroid cancer
Part of Cancer clinical trials.
This trial tests a combination of two drugs, pembrolizumab and lenvatinib, for people with a rare and aggressive thyroid cancer that cannot be removed by surgery. The goal is to see if this treatment can shrink the tumor or slow its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have anaplastic thyroid cancer that cannot be removed completely with surgery.
- You are 18 years old or older.
- You are able to care for yourself and are not bedridden (ECOG score 0-2).
- Your organs (like liver, kidneys, bone marrow) are working well enough.
- You have not had a specific BRAF mutation treated with targeted pills before.
- You do not have active bleeding, open wounds, or tumor growing into major blood vessels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two medications—zanzalintinib (a targeted drug that may stop cancer cells from growing) and cemiplimab (an immunotherapy that helps your immune system fight cancer)—for people with anaplastic thyroid cancer, a rare and aggressive type. The goal is to see if this combo helps shrink or control the cancer.
This trial tests whether giving a targeted therapy pill (which attacks cancer cells with a BRAF mutation) before and after surgery can help treat anaplastic thyroid cancer that hasn't spread to other organs. It's for people whose cancer has a specific gene change (BRAF V600E or V600K) and who are healthy enough for surgery.
This trial tests a combination of two drugs, XL092 and cemiplimab, for people with a rare and aggressive type of thyroid cancer called anaplastic thyroid cancer. The drugs aim to shrink tumors before surgery and help the immune system fight the cancer.
This trial tests a combination of two drugs, sinibolimab (an immunotherapy) and lenvatinib (a targeted therapy), given before surgery to shrink locally advanced thyroid cancer that cannot be fully removed. The goal is to make the tumor removable and improve outcomes.
This trial tests a new treatment for anaplastic thyroid cancer that combines two immune-based therapies: NKG2D CAR-NK cells (a type of white blood cell engineered to attack cancer) and a PD-1 inhibitor (a drug that helps the immune system fight cancer). The goal is to see if this combination is safe and effective.
This trial tests a combination of two oral and infused drugs to slow or shrink advanced thyroid cancer that has stopped responding to initial treatment. It may offer a new option for people with limited choices.
Hear when a new Anaplastic Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.